Immunome Doses First Patient in Phase 1 Trial of IM-1617
BOTHELL, Wash., June 11, 2026 Immunome, Inc. announced the first patient has been dosed in a Phase 1 first-in-human...
Phase 1 trial
Advertisement
Enliven Therapeutics Reports Positive ELVN-001 Phase 1 Data
BURLINGAME, Calif., June 11, 2026 Enliven Therapeutics announced updated positive Phase 1 clinical data for ELVN-001, its investigational BCR::ABL1-targeted...
Anixa Biosciences Highlights Clinical Immunotherapy Progress at Cancer Symposium
SAN JOSE, Calif., June 11, 2026 Anixa Biosciences, Inc. announced that two of its clinical-stage cancer immunotherapy programs will...
Formation Bio Doses First Participant in Phase 1 Trial of BLKR201, a CNS-Penetrant TYK2 Inhibitor
NEW YORK, June 9, 2026 Formation Bio announced the first participant has been dosed in a Phase 1 first-in-human...
Cellectis Secures FDA RMAT Status for Lasme-cel
NEW YORK, June 9, 2026 Cellectis announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine...
Advertisements
PureTech and Seaport Report Positive GlyphAgo Phase 1 Data
BOSTON, June 8, 2026 PureTech Health and its Founded Entity Seaport Therapeutics announced positive results from the multiple-ascending dose...
Corsair Pharma Showcases Positive Phase 1 TRX-248 Data at PHA 2026
NEWARK, Calif., June 8, 2026 Corsair Pharma, Inc. announced three presentations showcasing positive Phase 1 clinical data for its...
Antag Therapeutics Reports Positive Phase 1 Results for AT7687 in Obesity
COPENHAGEN, Denmark, June 7, 2026 Antag Therapeutics presented positive Phase 1 clinical results and new preclinical findings for AT7687,...
Shattuck Labs to Present Phase 1 Data for SL-325 on June 8
AUSTIN, Texas and DURHAM, N.C., June 5, 2026 Shattuck Labs announced that it will host an investor call and...
Climb Bio Advances CLYM116 After Encouraging Phase 1 Safety Results
WELLESLEY HILLS, Mass., June 5, 2026 Climb Bio, Inc. announced the presentation of initial Phase 1 safety data and...
Advertisement
